-
Orbit Genomics At MassChallenege Midpoint Road Show
Orbit Genomics thanks the MassChallenge community for an incredible Midpoint Road Show in Dallas last week! The energy, insight, and support from mentors and partners was invaluable—but what stood out most was the camaraderie among the cohort.We are surrounded by an inspiring group of founders who are each tackling MASSive problems in healthcare—from early cancer
-
Orbit Genomics Named As Finalist In 2024 Pepperdine Most Fundable Companies Competition
Orbit Genomics, Inc. has been named one of the 30 finalists for the Pepperdine Most Fundable Companies Competition, chosen from over 2,300 applicants. We would like to thank Pepperdine and the judges for this competition in recognizing the company for its efforts in developing highly accurate genomics tests for oncology, cardiovascular, longevity and other indications.
-
Orbit Genomics, Inc. was awarded a two-year, $2million Direct to Phase II SBIR Grant from NIH/NCI to develop a subtyping lung cancer blood test
Orbit Genomics was awarded a two-year $2MM Direct to Phase II SBIR Grant from NIH/NCI to develop the second-generation of our lung cancer test, OrbiSeq-L. OrbiSeq-L, is a simple blood test that diagnoses lung cancer in patients that have low-dose CT scans with indeterminate pulmonary nodules, IPNs. Every year, 2.5-3 million Americans have low-dose CT